Skip to main content
. 2014 Aug 21;50(5):564–572. doi: 10.1007/s00535-014-0987-2

Table 4.

Clinicopathological comparison of WDNEC and PDNEC

WDNEC (n = 4) PDNEC (n = 7)
Vascularity in pancreas tumor
 Yes (%) 50 % (2/4) 0 % (0/7)
Ki67 labeling index
 Median (range) 46.3 % (40–53 %) 85 % (54–95 %)
Rb immunopositivity 100 % (4/4) 14 % (1/7)
KRAS mutation 0 % (0/4) 86 % (6/7)
Response rate of platinum-based regimen 0 % (0/2) 100 % (4/4)
Prognosis
 Median 227 days 186 days

WDNEC well-differentiated NEC, PDNEC poorly differentiated NEC